PCSK9 and familial hypercholesterolemia: To our knowledge, this is the first comprehensive pharmacoeconomic comparison of all PCSK9 inhibitors currently marketed in China from the perspective of the Chinese healthcare system, evaluating primary prevention in hypercholesterolemia.